designer491
BridgeBio Pharma (NASDAQ:BBIO) has accused its rivals, Pfizer (NYSE:PFE) and Alnylam (NASDAQ:ALNY), of utilizing questionable ways to advertise their merchandise within the multibillion-dollar drug marketplace for a uncommon coronary heart dysfunction referred to as transthyretin cardiac amyloidosis, Bloomberg Information reported.
All three corporations
